Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer

Overview

Journal Intern Med

Specialty General Medicine

Date 2019 Nov 12

PMID 31708539

Citations 9

Authors

Nobumasa Ohara

Michi Kobayashi

Yohei Ikeda

Takahiro Hoshi

Shinichi Morita

Tsutomu Kanefuji

Kazuyoshi Yagi

Takeshi Suda

Toshinori Takada

Go Hasegawa

Yo Sato

Kenichiro Hirano

Shin-Ichi Kosugi

Affiliations

Soon will be listed here.

Abstract

A 70-year-old man with insulinoma-associated antigen-2 autoantibodies developed diabetes mellitus (DM) without ketoacidosis after starting nivolumab to treat advanced gastric cancer. He subsequently exhibited preserved insulin-secretion capacity for over one year. Immune checkpoint inhibitors (ICIs) infrequently cause type 1 DM associated with the rapid loss of insulin secretion and ketoacidosis as an immune-related adverse event. ICIs may also cause non-insulin-dependent DM by inducing insulin resistance if there is islet autoantibody-related latent beta-cell dysfunction. The present case highlights the importance of testing blood glucose levels regularly to diagnose DM in patients treated with ICIs, even if they do not have diabetic ketoacidosis.

Citing Articles

Impact of preoperative type 2 diabetes mellitus on the outcomes of patients with gastric cancer following gastrectomy: Analysis of 834 patients using propensity score matching.

Peng D, Xiang Y, Tang K, Qiu Y Biomed Rep. 2023; 19(6):97.

PMID: 37954633 PMC: 10633813. DOI: 10.3892/br.2023.1679.

Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab.

Zand Irani A, Gibbons H, Teh W BMJ Case Rep. 2023; 16(4).

PMID: 37011994 PMC: 10083744. DOI: 10.1136/bcr-2022-253696.

Pei W, Chen W, Wu Y, Tan S, Jie Z World J Gastrointest Oncol. 2023; 15(2):352-367.

PMID: 36908315 PMC: 9994050. DOI: 10.4251/wjgo.v15.i2.352.

PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.

Lin C, Li X, Qiu Y, Chen Z, Liu J Front Public Health. 2022; 10:885001.

PMID: 35991054 PMC: 9389003. DOI: 10.3389/fpubh.2022.885001.

Impact of Preoperative Type 2 Diabetes Mellitus on the Outcomes of Gastric Cancer Patients Following Gastrectomy: A Propensity Score Matching Analysis.

Cheng Y, Tao W, Kang B, Liu X, Yuan C, Zhang B Front Surg. 2022; 9:850265.

PMID: 35350140 PMC: 8957786. DOI: 10.3389/fsurg.2022.850265.

References

Winter W, Schatz D . Autoimmune markers in diabetes. Clin Chem. 2010; 57(2):168-75. DOI: 10.1373/clinchem.2010.148205. View

Kotwal A, Haddox C, Block M, Kudva Y . Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019; 7(1):e000591. PMC: 6398813. DOI: 10.1136/bmjdrc-2018-000591. View

Michot J, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54:139-148. DOI: 10.1016/j.ejca.2015.11.016. View

Iyer P, Cabanillas M, Waguespack S, Hu M, Thosani S, Lavis V . Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid. 2018; 28(10):1243-1251. PMC: 6157359. DOI: 10.1089/thy.2018.0116. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013; 37 Suppl 1:S81-90. DOI: 10.2337/dc14-S081. View

Godwin J, Jaggi S, Sirisena I, Sharda P, Rao A, Mehra R . Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017; 5:40. PMC: 5433051. DOI: 10.1186/s40425-017-0245-2. View

Gauci M, Boudou P, Baroudjian B, Vidal-Trecan T, Meda L, Madelaine-Chambrin I . Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study. Cancer Immunol Immunother. 2018; 67(8):1197-1208. PMC: 11028208. DOI: 10.1007/s00262-018-2178-0. View

Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H . Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig. 2016; 7(6):915-918. PMC: 5089956. DOI: 10.1111/jdi.12531. View

Usui Y, Udagawa H, Matsumoto S, Imai K, Ohashi K, Ishibashi M . Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 12(5):e41-e43. DOI: 10.1016/j.jtho.2016.12.015. View

10.

Buzzetti R, Zampetti S, Maddaloni E . Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017; 13(11):674-686. DOI: 10.1038/nrendo.2017.99. View

11.

Stamatouli A, Quandt Z, Perdigoto A, Clark P, Kluger H, Weiss S . Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018; 67(8):1471-1480. PMC: 6054443. DOI: 10.2337/dbi18-0002. View

12.

Gauci M, Boudou P, Squara P, Delyon J, Allayous C, Mourah S . Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. Melanoma Res. 2019; 29(3):328-332. DOI: 10.1097/CMR.0000000000000585. View

13.

Clotman K, Janssens K, Specenier P, Weets I, De Block C . Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018; 103(9):3144-3154. DOI: 10.1210/jc.2018-00728. View

14.

Galligan A, Xu W, Fourlanos S, Nankervis A, Chiang C, Mant A . Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabet Med. 2018; . DOI: 10.1111/dme.13762. View

15.

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

16.

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

17.

Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z . Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab. Tohoku J Exp Med. 2018; 244(1):33-40. DOI: 10.1620/tjem.244.33. View

18.

Barroso-Sousa R, Barry W, Garrido-Castro A, Hodi F, Min L, Krop I . Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2017; 4(2):173-182. PMC: 5838579. DOI: 10.1001/jamaoncol.2017.3064. View

19.

Borg H, Gottsater A, Fernlund P, Sundkvist G . A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes. 2002; 51(6):1754-62. DOI: 10.2337/diabetes.51.6.1754. View

20.

Baden M, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y . Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019; 10(1):58-66. PMC: 6357237. DOI: 10.1007/s13340-018-0362-2. View